US EditionPublished • loading... • Updated
Glp-1 Receptor Agonists and Progestins May Protect Against Uterine Cancer in Benign Precursor Lesions.
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Baltimore/Taichung – In addition to standard progestin therapies, GLP-1 receptor agonists (GLP-1 RAs) could protect against the progression of benign uterine changes to endometrial cancer. In an international retrospective cohort study, the cancer incidence with additional GLP-1 RA therapy was approximately one-third of that seen without...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
